Collegium Pharmaceutical Management
Management criteria checks 2/4
Collegium Pharmaceutical's CEO is Vikram Karnani, appointed in Nov 2024, has a tenure of 1.08 years. total yearly compensation is $10.78M, comprised of 0.9% salary and 99.1% bonuses, including company stock and options. directly owns 0.055% of the company’s shares, worth $825.21K. The average tenure of the management team and the board of directors is 2.4 years and 10.2 years respectively.
Key information
Vikram Karnani
Chief executive officer
US$10.8m
Total compensation
| CEO salary percentage | 0.91% |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.06% |
| Management average tenure | 2.4yrs |
| Board average tenure | 10.2yrs |
Recent management updates
Recent updates
Collegium Pharmaceutical: Another Solid Quarter
Nov 10Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 28% Jump Shows Its Popularity With Investors
Nov 08
We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt
Oct 19Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) P/E Still Appears To Be Reasonable
Jul 31There May Be Reason For Hope In Collegium Pharmaceutical's (NASDAQ:COLL) Disappointing Earnings
May 16Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Has Caught The Eye Of Investors
Apr 07Collegium Pharmaceutical: Checking The Boxes
Mar 03Improved Revenues Required Before Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Find Their Feet
Dec 24Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion
Nov 26Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality
Nov 14Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Oct 28
Ironshore Acquisition And Calculated Moves Set To Propel Growth In ADHD Market
Collegium Pharmaceutical's acquisition of Ironshore Therapeutics positions them in the ADHD market, aiming for revenue growth through diversified offerings and operational efficiencies.Collegium Pharmaceutical: Diversifying And Growing
Aug 09Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking
Jul 24Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly
Jun 05Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'
May 13It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package
May 10Collegium Pharmaceutical Q4: The Beat Goes On
Feb 26These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues
Jan 05Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$58m |
| Jun 30 2025 | n/a | n/a | US$36m |
| Mar 31 2025 | n/a | n/a | US$44m |
| Dec 31 2024 | US$11m | US$98k | US$69m |
Compensation vs Market: Vikram's total compensation ($USD10.78M) is above average for companies of similar size in the US market ($USD5.44M).
Compensation vs Earnings: Insufficient data to compare Vikram's compensation with company performance.
CEO
Vikram Karnani (50 yo)
Mr. Vikram Karnani is Director of Dyne Therapeutics, Inc. from December 2025. Mr. Karnani is CEO, President & Director of Collegium Pharmaceutical, Inc. since November 12, 2024 and serves as its Executive...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 1.1yrs | US$10.78m | 0.055% $ 825.2k | |
| Executive VP & CFO | 4.6yrs | US$3.19m | 0.038% $ 567.9k | |
| Executive VP & Chief Commercial Officer | 7.4yrs | US$2.79m | 0% $ 0 | |
| Executive VP & Chief Medical Officer | 3.8yrs | US$2.50m | 0.00086% $ 12.8k | |
| Head of Investor Relations | no data | no data | no data | |
| Executive VP | less than a year | no data | no data | |
| Executive Vice President of Strategy & Corporate Development | less than a year | no data | no data | |
| Chief People Officer | less than a year | no data | no data | |
| Head of Technical Operations | 4.2yrs | no data | no data |
Experienced Management: COLL's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 1.1yrs | US$10.78m | 0.055% $ 825.2k | |
| Independent Director | 11.8yrs | US$339.02k | 0.13% $ 2.0m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 10.9yrs | US$339.02k | 0.0071% $ 106.2k | |
| Independent Chairman | 13.4yrs | US$362.02k | 0.11% $ 1.7m | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 9.5yrs | US$328.02k | 0.17% $ 2.6m | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data |
Experienced Board: COLL's board of directors are seasoned and experienced ( 10.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/31 14:37 |
| End of Day Share Price | 2025/12/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Collegium Pharmaceutical, Inc. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jenna Davidner | Barclays |
| Dana Flanders | Guggenheim Securities, LLC |
| Antonio Arce | H.C. Wainwright & Co. |